The problem with existing fall risk assessments is stark. Most screening tools rely on physical performance measures such as gait and balance testing, with cutoff points derived from studies of adults aged 65 and older that included few or no participants over 90. Applied to a 93-year-old, nearly every one of these tools would flag the patient as high risk. But fewer than half of people aged 90 and older actually fall each year. Labeling everyone as high risk is not merely imprecise; it is actively harmful. Hospital patients tagged as fall risks are often kept in bed without assistance, which accelerates deconditioning and immobility. A high-risk label can also make it harder for clinicians to justify discharge home or to intensive rehabilitation, limiting access to restorative care for an already vulnerable group and feeding the already high rates of institutionalization among the oldest old.

To cut through this diagnostic fog, the research team led by Katherine A. Colcord and María M. Corrada analyzed 1,099 participants from The 90+ Study—749 women and 350 men with a mean age of 93.2 years. The cohort, largely drawn from surviving members of the Leisure World Cohort Study, a landmark epidemiological project begun in 1981 in a California retirement community, was evaluated every six months. At each visit, examiners recorded falls reported by participants or their informants, administered the Four-Meter Walk Test, and assigned a cognitive diagnosis ranging from normal to cognitive impairment no dementia (CIND) to dementia. The researchers then classified each participant into four groups: neither slow gait nor impaired cognition, slow gait alone, impaired cognition alone, or both.

The gait measure was deliberately tailored to this age group. Rather than using the conventional 1.0 meter-per-second threshold developed in younger populations—a cutoff that would have classified 93 percent of the study participants as slow walkers—the team defined slow gait as a speed below the sex-specific median: 0.56 meters per second for women and 0.69 meters per second for men. These values closely match published reference percentiles for adults over 90, allowing the investigators to distinguish relatively slower walkers within the cohort rather than simply sorting nearly everyone into the same bucket. The Four-Meter Walk Test itself is elegantly simple: participants walk four marked meters at their usual pace, timed from the moment the first foot crosses the starting tape to when it crosses the finish line, with buffer zones for acceleration and deceleration.

Using generalized linear mixed regression models with a negative binomial distribution and log person-years as an offset, the team calculated incidence rate ratios comparing each gait-cognition group against the reference group with neither deficit. The results, published in September 2026, revealed a striking sex difference. Among women, slow gait alone raised fall risk by 33 percent and the combination of slow gait and impaired cognition by 35 percent, but impaired cognition by itself showed no significant association. Among men, all three categories mattered: slow gait alone raised risk by 70 percent, impaired cognition alone by 75 percent, and the combination by a full 134 percent compared with men who had neither deficit. Adjusting for demographics and for a comorbidity index spanning seventeen chronic conditions did not meaningfully change these patterns, suggesting the associations were not driven by overall disease burden.

The sex difference persisted in sensitivity analyses designed to probe its robustness. Among the 604 participants who walked without any assistive device—people who might not otherwise be flagged as vulnerable—the combination of slow gait and impaired cognition was a powerful predictor, raising fall risk more than twofold overall, with significant effects in both women and men. In the subgroup of 596 participants who reported no falls at or before their baseline visit, impaired cognition and the combined deficit remained significant predictors in men but not women, indicating that the male associations were not simply an artifact of a prior history of falling. When the researchers re-included 110 participants who were unable to complete the walk test—counting them as slow walkers, since inability to finish likely reflects poor physical function—the combined group predicted falls in both sexes, and the magnitude of the risk estimates grew slightly, hinting that the true associations may be even stronger than observed.

The longitudinal trajectories added another layer of insight. In men, fall rates climbed steadily over time in the groups with neither deficit, slow gait alone, or impaired cognition alone, but remained consistently high from the start in the combined group. In women, fall rates rose significantly only in the group with neither deficit and stayed relatively flat elsewhere. This pattern carries a double message: the combination of slow gait and impaired cognition identifies people whose risk is persistently elevated, while even those who appear entirely healthy at 93 face rising risk as time passes. Continued fall screening, the authors argue, must not stop at age 90.

Why should cognition and gait be more predictive together than either alone? Several mechanisms have been proposed. Cognitive impairment erodes judgment and self-awareness, leading people to place themselves in precarious situations they can no longer safely navigate. Neuropathological changes in the brain that drive cognitive decline may simultaneously drive physical decline, so cognition testing can catch subtle deterioration in balance, postural control, and reaction time that gait speed alone misses. Medications matter too: cholinesterase inhibitors prescribed for cognitive impairment can cause dizziness and lightheadedness, indirectly raising fall risk. The findings echo earlier work in younger seniors—a meta-analysis of 6,204 participants with a mean age of 74.9 found a 44 percent higher fall risk in people with both slow gait and subjective cognitive complaints—but the new study extends this evidence into the ninth decade of life, where the stakes are highest.

The sex difference itself may have a surprisingly practical explanation. In the cohort, women used walkers more often than canes, while men favored canes. Canes demand greater cognitive capacity for sequencing and timing during gait and require more energy expenditure, and previous work from the same group found that walker use was associated with a declining fall rate over time while cane use was associated with an increasing one. A cane may simply be the wrong prescription for a cognitively impaired 93-year-old, and the authors suggest that referral to a clinician trained in gait analysis before prescribing an assistive device could itself become a fall prevention strategy. The study is not without limitations—falls were self-reported at six-month intervals, which may have led cognitively impaired participants to underreport and thus underestimate the cognitive effect, and the cohort was 98.6 percent White—but its inclusion of homebound participants, with examiners traveling even out of state, makes it unusually representative of the real 90-plus population.

The implications reach well beyond the clinic. As the oldest old become a larger share of society, distinguishing who truly needs fall precautions from who does not could preserve mobility, independence, and dignity for millions. This study shows that a stopwatch, a four-meter hallway, and a careful cognitive assessment—together, not separately—can do what decades of age-based screening could not: find the people who are genuinely about to fall, before they do.

Subject of Research: The combined role of gait speed and cognitive impairment in predicting fall risk among adults aged 90 and older

Article Title: Enhancing fall risk assessment in the oldest old: The interplay of cognition and gait speed

Article References: Colcord, K. A., Kristinsson, H. B., Jiang, L., Melikyan, Z. A., Al-darsani, Z., Falvey, J. R., Kawas, C. H., & Corrada, M. M. (2026). Enhancing fall risk assessment in the oldest old: The interplay of cognition and gait speed. GeroScience. https://doi.org/10.1007/s11357-026-02516-0

Image Credits: AI Generated

DOI: 10.1007/s11357-026-02516-0

Keywords: fall risk, oldest old, gait speed, cognitive impairment, dementia, The 90+ Study, geroscience, fall prevention, aging, sex differences, Four-Meter Walk Test, assistive devices

The research, led by Mirko Di Rosa and Luca Soraci of IRCCS INRCA in Cosenza, Italy, together with colleagues at the University of Calabria and partner institutions, pooled individual-level data from four prospective European cohorts of older adults. The cohorts were deliberately heterogeneous: 812 community-dwelling older people from the ECHA-PC-MUSA studies, 813 nursing home residents from the SADEL cohort, 579 long-lived individuals and area-matched controls from the Genetics of Healthy Ageing project, and 4,400 hospitalized patients from the REPORTAGE project. In total, 6,604 people were followed for up to five years, and the mean age of the pooled sample was 84.8 years, with a standard deviation of 9.2 years. That breadth of settings is precisely what makes the analysis unusual; most previous studies of RDW and mortality have examined a single clinical population, leaving open the question of whether the marker truly travels across the diverse worlds of home, hospital, and long-term care.

Technically, RDW is reported as a coefficient of variation, the standard deviation of red cell volume divided by the mean corpuscular volume, multiplied by one hundred. It is generated automatically by automated haematology analysers at no additional cost, which is part of its appeal as a potential screening tool. In this study the primary exposure was an RDW-CV of 15 percent or higher, a threshold commonly used to flag anisocytosis, the technical term for increased variability in red cell size. Among the European participants, 41.4 percent met this criterion, and over the five-year follow-up period 69.9 percent of the cohort died, a striking figure that reflects the advanced age and clinical vulnerability of the populations studied.

To test whether elevated RDW was an independent predictor of death rather than a bystander marker of known risk factors, the investigators used multilevel Cox proportional hazards regression, treating the cohort of origin as a random effect. The models adjusted for a formidable battery of geriatric prognostic factors: age, sex, the presence of anaemia, serum albumin, the neutrophil-to-lymphocyte ratio as an index of systemic inflammation, the number of chronic diseases and medications, and impairment in activities of daily living. The models also pre-specified stratification at age 85, allowing the association to be examined separately in the oldest-old, a group in which mortality prediction is notoriously difficult because standard risk factors often lose discriminatory power.

The headline result was unambiguous. Older adults with RDW-CV at or above 15 percent had a 58 percent higher hazard of death during follow-up than those below the threshold, with a pooled adjusted hazard ratio of 1.58 and a 95 percent confidence interval running from 1.48 to 1.68, a finding highly statistically significant at p less than 0.001. Just as important as the magnitude was the consistency: between-cohort heterogeneity, quantified by the theta statistic, was minimal at 0.06, and the direction of the association was concordant in three of the four cohorts. In epidemiological terms, this suggests that the relationship is not an artefact of any single population or care setting but a robust phenomenon that persists whether the blood was drawn in a nursing home, a hospital ward, or a community clinic.

Replication is where many biomarker studies falter, so the team took the additional step of validating their findings externally in an entirely different healthcare system. They analysed 2,471 participants from the 2016 wave of the Health and Retirement Study, a large, nationally representative survey of older Americans. Once again, the elevated-RDW group showed significantly higher mortality, with a hazard ratio whose 95 percent confidence interval extended from 1.23 to 2.19 and a p value below 0.001. The fact that the association survived in a transatlantic sample, with different ancestry profiles, laboratory platforms, and care structures, strengthens the case that RDW captures something fundamental about biological risk rather than a local idiosyncrasy of Italian geriatric medicine.

Why should the variability of red blood cell size carry information about survival? The most widely discussed mechanism implicates chronic, low-grade systemic inflammation and its effects on erythropoiesis, the production of red cells in the bone marrow. Inflammatory cytokines disturb iron metabolism, shorten red cell lifespan, and disrupt the careful regulation of cell volume during maturation, producing a wider distribution of cell sizes. Elevated RDW has also been linked to oxidative stress, nutritional deficiencies, renal dysfunction, and subtle derangements of haematopoietic stem cell dynamics. In this sense, the authors argue, RDW may act as an integrative readout of physiological dysregulation, a single number that summarises the accumulated wear on multiple organ systems. Its independence from the neutrophil-to-lymphocyte ratio and albumin in the adjusted models suggests it is not simply proxying inflammation or malnutrition but adds a distinct dimension of prognostic information.

The association was strongest in the oldest-old, participants aged 85 and above, which is where the clinical implications become most interesting. Predicting mortality in very old patients is a persistent challenge for geriatric medicine; chronological age alone is a blunt instrument, and comprehensive geriatric assessment, while valuable, is time-consuming and requires trained personnel. A marker that costs nothing extra, is already reported on every blood count, and performs at a fixed cut-off across community, nursing home, and hospital populations could help clinicians stratify risk quickly at the bedside. It might, for example, inform decisions about the intensity of investigations, the appropriateness of aggressive interventions, or the prioritisation of patients for closer monitoring. The researchers are careful, however, to frame RDW as a prognostic indicator, not a deterministic verdict; a hazard ratio of 1.58 describes average risk at the population level, and individual outcomes will vary widely.

Several caveats temper the enthusiasm. This is an observational analysis, so elevated RDW identifies association rather than proven causation, and there is as yet no evidence that lowering RDW would change survival. The exposure was measured at a single time point, leaving open questions about the value of tracking RDW trajectories over time, and although the adjustment set was unusually comprehensive for a biomarker study, residual confounding can never be fully excluded. The predominance of Italian cohorts in the pooled European sample also invites replication in other national contexts, even given the American validation. Nonetheless, the study clears a high bar: a fixed, pre-specified threshold, individual-level pooling across markedly different care settings, adjustment for the major geriatric prognostic factors including anaemia, functional status, inflammation, and nutrition, minimal heterogeneity, and external replication in a second continent. Few routinely available laboratory measures can claim a comparable evidentiary pedigree.

The broader lesson may be about where medicine should look for its next generation of risk markers. As automated analysers quietly compute dozens of derived indices with every routine sample, some of the most informative signals may already be sitting in electronic health records, unexamined. Red cell distribution width, a number most patients have never heard of, now has credible evidence behind it as an independent predictor of five-year mortality in older adults across the full spectrum of care, from independent living to intensive hospital treatment. For a rapidly ageing global population, and for clinicians searching for cheap, scalable tools to guide geriatric care, a modest column of digits on a standard blood report may prove to be one of the most consequential numbers in the chart.

Subject of Research: Red cell distribution width as an independent predictor of five-year all-cause mortality in older adults across diverse care settings

Article Title: Red cell distribution width and 5-year mortality across older adult care settings: a pooled European cohort analysis with US validation

Article References: Red cell distribution width and 5-year mortality across older adult care settings: a pooled European cohort analysis with US validation. (n.d.). https://doi.org/10.1186/s12967-026-08997-z

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08997-z

Keywords: red cell distribution width, RDW, mortality, aging, geriatrics, complete blood count, oldest old, prognosis, cohort study, anaemia, inflammation, biomarker